Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - AUXILIUM PHARMACEUTICALS INC | a12-13593_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 4, 2012
Auxilium Pharmaceuticals, Inc.
(Exact Name of Registrant Specified in Charter)
Delaware |
|
000-50855 |
|
23-3016883 |
(State or Other |
|
(Commission File |
|
(I.R.S. Employer |
40 Valley Stream Parkway |
|
|
Malvern, PA |
|
19355 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (484) 321-5900
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
On June 4, 2012, Auxilium Pharmaceuticals, Inc. (Auxilium) issued a press release announcing positive top-line results from both Phase III trials of XIAFLEX® for the potential treatment of Peyronies disease where XIAFLEX demonstrated statistically significant improvement in the co-primary endpoints of penile curvature deformity and patient-reported bother versus placebo in IMPRESS I and II.
Auxilium also announced in the press release that it will host a conference call and webcast on Monday, June 4 at 8:00 a.m. Eastern Time, to discuss the results of the Phase III trials for XIAFLEX for the treatment of Peyronies disease in greater detail.
The full text of such press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
99.1 |
|
Press Release, dated June 4, 2012, issued by Auxilium Pharmaceuticals, Inc. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AUXILIUM PHARMACEUTICALS, INC. | |
|
| |
|
| |
Date: June 4, 2012 |
By: |
/s/ Andrew I. Koven |
|
|
Andrew I. Koven |
|
|
Chief Administrative Officer and General Counsel |